Dr Dionysis Papadatos-Pastos | London Lung Oncologist

I am a London based oncologist, specialist in the treatment of lung cancer, mesothelioma and thymic tumors.

I offer my patients a personalized, compassionate approach rooted in my extensive experience as an oncologist. I tailor each treatment plan to the individual, ensuring the most effective therapies are used while considering each patient’s unique circumstances. The holistic approach emphasizes not only medical care but also emotional and psychological support, including guidance for family members throughout the cancer journey. My patients benefit from a dedicated team that understands the importance of comprehensive, family-centered cancer care.

Learn more

Conditions treated

Comprehensive thoracic cancer treatment

Testimonials

What Our Patients Are Saying

Clinics

Harley Street & Chelsea

View
Clinical trials

Clinical trials are crucial in advancing lung cancer treatment, offering patients access to cutting-edge therapies...

Recent Advances in the Treatment of EGFR (common mutations)-Driven Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is one of the most common and deadliest cancers worldwide, and about 85%...

Targeted therapies in NSCLC

Targeted therapies have revolutionized the treatment of non-small cell lung cancer (NSCLC), offering more personalized...

Advanced stage small cell lung cancer

Extensive-stage small cell lung cancer (SCLC) is a challenging diagnosis, as it indicates the cancer...

Why surgery should not be routinely used in patients with mesothelioma

The MARS2 trial (Mesothelioma and Radical Surgery 2) was designed to evaluate the effectiveness of...

Immunotherapy in NSCLC

Immunotherapy has transformed the treatment landscape for non-small cell lung cancer (NSCLC), offering new hope,...

Early stage small cell lung cancer

The treatment of early-stage small cell lung cancer (SCLC) has traditionally involved a combination of...

New Hope for B3 Thymoma and Thymic Carcinoma: Promising Results from Lenvatinib and Pembrolizumab Combination Therapy

The PECATI trial, presented at ESMO 2024, brings promising news for patients with advanced B3...

Treatment of ROS1-Driven Lung Cancer: A Comprehensive Overview

Lung cancer remains one of the most common and lethal cancers worldwide, but advances in...

Understanding ALK-Driven Non-Small Cell Lung Cancer (NSCLC)

Anaplastic Lymphoma Kinase (ALK)-driven non-small cell lung cancer (NSCLC) is a subtype of lung cancer...

Newspapers And Media

Media

Discussing Antibody Drug Conjugates in NSCLC

Resources for physicians: Discussing Antibody Drug Conjugates in NSCLCResources for physicians: Dr Papadatos-Pastos presentation on...

To intensify or not to intensify 1L treatment in EGFR-Mutated NSCLC?

Resources for physicians: Dr Papadatos-Pastos presentation on 1st line treatment for EGFR driven non small...

Dr Papadatos-Pastos in the Evening Standard (10 September 2024)

Hopeful horizons for lung cancer patients As seen in the Evening Standard newspaper on September...

Dr Papadatos-Pastos at the 5th International Meeting on Lung Cancer

The 5th International Meeting on Lung Cancer was a highly successful event, bringing together leading...